Biotricity is trading 13.83% down now at $0.10 as U.S. equities weaken amid geopolitical tensions, higher oil prices, rising bond yields, and softer labor and manufacturing data.
- No clear company-specific announcement surfaced in the reviewed September 1 coverage.
- Healthcare is outperforming, making broader risk-off sentiment and Biotricity’s recent volatility more consistent explanations than sector weakness.